• Our products

  • 1

Metabolic & GI Disease

PYLERA® (bismuth subcitrate potassium, metronidazole, tetracycline HCl) in combination with omeprazole, is a 3-in-1 capsule for the first line option in the eradication treatment of H. pylori. The eradication of Helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence as well as reduce the risk of gastric cancer. Bismuth based quadruple therapy is first line in most international guidelines for H Pylori treatment.

DIBASE, is a drug based on the active substance Cholecalciferol, it Is an oral solution contains cholecalciferol (vitamin D3 )in an olive oil solution used in the prevention and treatment of Vitamin D Deficiency.

COLLATAMP®G is a locally haemostatic device of type I collagen.8, Medical device – class III, it is a gentamicin-collagen implant used during cardiac2, vascular3, orthopaedic4, gastro-intestinal5 surgery as well in electrocardiology.6. It is used for local haemostasis of capillary, parenchymatous and seeping haemorrhages in areas with a high risk of infection. This product contains gentamicin sulphate at a locally effective dose. Systemically effective therapeutic blood or plasma levels are not generally achieved.1

GLICONORM™, Glibenclamide + Metformin hydrochloride, is a second line therapy to treat non-insulin dependent diabetes mellitus. This fixed dose in one tablet provides convenience for patients and helps increase patient compliance.

VERIFI Plus®, is a non-invasive prenatal test (NIPT), offering early genetic screening for chromosomal abnormalities using just one tube of blood—as early as 10 weeks into a patient’s pregnancy. Verifi analyzes cell free fetal and maternal DNA from a blood sample to screen for common chromosome conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Verifi poses minimal risk to the mother or baby with high detection rates and low false positives.

AFIRMA® Thyroid FNA Analysis is a comprehensive solution that combines the advantages of specialized cytopathology with the power of genomics. Afirma GEC analyzes the expression level of 142 different genes. Together, these genes demonstrate a recognizable pattern of expression in benign thyroid nodules. Afirma can help doctors identify benign nodules when cytopathology is indeterminate, thereby reducing the number of unnecessary thyroid surgeries. And, if the patient needs surgery, Afirma can also provide valuable additive information that may help guide decisions on the appropriate surgery – all from one FNA.

*for full prescribing information please refer to your locally approved label*


  • 1